Richard Marais | Academic Influence

Richard Marais's AcademicInfluence.com Rankings

Richard Marais

Law

#2255

World Rank

#2822

Historical Rank

Common Law

#80

World Rank

#88

Historical Rank

Download Badge

Law

Richard Marais's Degrees

Bachelors Biology University of Oxford

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2025

Why Is Richard Marais Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Richard Malcolm Marais is Director of the Cancer Research UK Manchester Institute and Professor of Molecular Oncology at the University of Manchester. Education Marais was educated at University College London where he was awarded a Bachelor of Science degree in Genetics and Microbiology in 1985. He completed his postgraduate study at the Ludwig Institute for Cancer Research and was awarded a PhD in 1989 for research on isotypes of the protein kinase C enzyme supervised by Peter Parker.

(See a Problem?)

Richard Marais's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Mutations of the BRAF gene in human cancer (2002) (9903)
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF (2004) (2524)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF (2010) (1366)
The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain (1993) (1335)
Melanoma biology and new targeted therapy (2007) (1295)
The RAF proteins take centre stage (2004) (1162)
Guilty as charged: B-RAF is a human oncogene. (2004) (835)
Activation of the Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathway by Conventional, Novel, and Atypical Protein Kinase C Isotypes (1998) (807)
The role of signaling pathways in the development and treatment of hepatocellular carcinoma (2010) (784)
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity (2015) (721)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis (2006) (645)
Ras recruits Raf‐1 to the plasma membrane for activation by tyrosine phosphorylation. (1995) (643)
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. (2012) (610)
Oncogenic Braf induces melanocyte senescence and melanoma in mice. (2009) (534)
Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases* (1997) (469)
Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. (1998) (469)
Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation (1999) (457)
Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling (2015) (453)
B-RAF is a therapeutic target in melanoma (2004) (451)
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. (2005) (404)
Cellular senescence in naevi and immortalisation in melanoma: a role for p16? (2006) (395)
Functional analysis of a growth factor-responsive transcription factor complex (1993) (379)
ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. (2011) (360)
V599EB-RAF is an Oncogene in Melanocytes (2004) (357)
SF3B1 mutations are associated with alternative splicing in uveal melanoma. (2013) (331)
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. (2013) (314)
MEK kinase activity is not necessary for Raf‐1 function (2001) (308)
Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways (2005) (305)
ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. (2006) (300)
Control of the ERK MAP kinase cascade by Ras and Raf. (1996) (273)
New insight into BRAF mutations in cancer. (2007) (266)
Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF (2008) (260)
Protein kinase C — a family affair (1989) (248)
Protein Kinase A Blocks Raf-1 Activity by Stimulating 14-3-3 Binding and Blocking Raf-1 Interaction with Ras* (2003) (245)
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. (2005) (235)
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. (2006) (232)
Elucidating distinct roles for NF1 in melanomagenesis. (2013) (212)
Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation (2005) (206)
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. (2011) (205)
Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. (2009) (202)
Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53 (2014) (201)
Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy (2015) (199)
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations (2018) (196)
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice (2011) (193)
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. (2011) (192)
Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. (2016) (189)
Calmodulin Binds to K-Ras, but Not to H- or N-Ras, and Modulates Its Downstream Signaling (2001) (187)
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. (2005) (185)
BRAF signaling and targeted therapies in melanoma. (2009) (183)
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy (2016) (181)
Spatial flexibility in ternary complexes between SRF and its accessory proteins. (1992) (178)
The role of B-RAF in melanoma (2005) (173)
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma (2015) (171)
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study (2019) (171)
Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. (2005) (164)
The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα. (2014) (164)
Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies (2010) (163)
Regulation of Mitogen-Activated Protein Kinases in Cardiac Myocytes through the Small G Protein Rac1 (2001) (161)
Whole genome sequencing of matched primary and metastatic acral melanomas. (2012) (161)
Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma (2013) (153)
FGF‐2 protects small cell lung cancer cells from apoptosis through a complex involving PKCε, B‐Raf and S6K2 (2006) (151)
Casein kinase II phosphorylation increases the rate of serum response factor‐binding site exchange. (1992) (150)
Diverse matrix metalloproteinase functions regulate cancer amoeboid migration (2014) (150)
FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. (2006) (135)
Purification and characterisation of bovine brain protein kinase C isotypes α, β and γ (1989) (134)
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. (2012) (130)
Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells (2015) (130)
14-3-3 Antagonizes Ras-Mediated Raf-1 Recruitment to the Plasma Membrane To Maintain Signaling Fidelity (2002) (125)
The Brn-2 Transcription Factor Links Activated BRAF to Melanoma Proliferation (2004) (124)
V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a (2010) (122)
Ras Subcellular Localization Defines Extracellular Signal-Regulated Kinase 1 and 2 Substrate Specificity through Distinct Utilization of Scaffold Proteins (2008) (121)
BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling (2014) (119)
Localization of O-GlcNAc modification on the serum response transcription factor. (1992) (118)
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. (2011) (118)
B-Raf Acts via the ROCKII/LIMK/Cofilin Pathway To Maintain Actin Stress Fibers in Fibroblasts (2004) (116)
Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients (2018) (114)
Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy (2019) (113)
Ras protein signalling. (2000) (112)
Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma (2017) (111)
Regulation of Ras·GTP Loading and Ras-Raf Association in Neonatal Rat Ventricular Myocytes by G Protein-coupled Receptor Agonists and Phorbol Ester (1999) (110)
Regulation of GATA-2 Phosphorylation by Mitogen-activated Protein Kinase and Interleukin-3 (*) (1995) (106)
Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. (1996) (105)
Phosphorylation and activation of B-Myb by cyclin A–Cdk2 (1997) (105)
In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. (2007) (103)
The endocytic protein intersectin is a major binding partner for the Ras exchange factor mSos1 in rat brain (2000) (99)
The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. (2018) (99)
Tumor Necrosis Factor-α Blocks Apoptosis in Melanoma Cells when BRAF Signaling Is Inhibited (2007) (98)
Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors (2009) (95)
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR (2015) (95)
The mutational burden of acral melanoma revealed by whole‐genome sequencing and comparative analysis (2014) (94)
Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma (2012) (89)
Neuron-specific protein F1/GAP-43 shows substrate specificity for the beta subtype of protein kinase C. (1990) (87)
CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. (2008) (85)
Cyclic AMP Blocks Cell Growth through Raf-1-Dependent and Raf-1-Independent Mechanisms (2002) (83)
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity (2021) (82)
Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. (2010) (82)
Gene-directed enzyme prodrug therapy. (1998) (79)
A Braf kinase-inactive mutant induces lung adenocarcinoma (2017) (75)
Consensus on precision medicine for metastatic cancers: a report from the MAP conference. (2016) (75)
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) (75)
S338 Phosphorylation of Raf-1 Is Independent of Phosphatidylinositol 3-Kinase and Pak3 (2001) (72)
A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy (1997) (71)
A mouse model of melanoma driven by oncogenic KRAS. (2010) (71)
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors (2014) (70)
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors (2008) (70)
Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma (2016) (69)
Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma (2009) (68)
Ultraviolet radiation–induced DNA damage is prognostic for outcome in melanoma (2018) (68)
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma (2021) (68)
Attenuated Salmonella Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective Suicide Gene Therapy (2008) (68)
MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma (2017) (67)
ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf (2002) (67)
A whole‐genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor‐negative and ‐positive breast cancers (2012) (65)
The phosphorylation of protein kinase C as a potential measure of activation. (1989) (64)
ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers (2013) (62)
Raf Inhibitors Target Ras Spatiotemporal Dynamics (2012) (62)
Calmodulin Prevents Activation of Ras by PKC in 3T3 Fibroblasts* (2002) (60)
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. (2012) (60)
Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. (2007) (58)
Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. (2013) (57)
Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface (2017) (57)
Metformin: a diabetes drug for cancer, or a cancer drug for diabetics? (2012) (56)
A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity (2015) (56)
Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. (2007) (56)
Small molecule inhibitors of BRAF in clinical trials. (2012) (55)
BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. (2004) (54)
No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients (2014) (53)
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition (2014) (53)
Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. (2000) (51)
Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients (2005) (51)
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA (2016) (50)
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. (2019) (49)
Melanoma models for the next generation of therapies. (2021) (49)
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. (2006) (49)
The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival (2021) (47)
Radioactive labeling of recombinant antibody fragments by phosphorylation using human casein kinase II and [γ-32P]-ATP (1996) (44)
Genomic characterisation of acral melanoma cell lines (2012) (43)
BRAF inactivation drives aneuploidy by deregulating CRAF. (2010) (43)
Combined zebrafish-yeast chemical-genetic screens reveal gene–copper-nutrition interactions that modulate melanocyte pigmentation (2010) (42)
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies (2011) (41)
Next-Generation Sequencing Analysis and Algorithms for PDX and CDX Models (2017) (40)
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. (2019) (40)
BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress. (2015) (40)
Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring. (2009) (39)
MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells. (2013) (39)
The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate–Lactate Exchange in BRAF-Mutant Human Melanoma Cells (2016) (39)
Studies on the primary sequence requirements for PKC‐α, ‐β1 and ‐γ peptide substrates (1990) (38)
Importance of low affinity Elf-1 sites in the regulation of lymphoid- specific inducible gene expression (1996) (38)
COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors (2014) (37)
Heterogeneity of protein kinase C expression and regulation in T lymphocytes (1990) (37)
A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression (2005) (37)
Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. (2002) (37)
Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors. (2010) (36)
Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF). (2009) (36)
Self-immolative anthracycline prodrugs for suicide gene therapy. (1999) (36)
Monoclonal antibodies to protein kinase Cγ (1989) (35)
Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure–Activity Relationships (2019) (34)
So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020 (2019) (33)
BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors (2016) (33)
Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. (2005) (33)
Self-immolative nitrogen mustard prodrugs for suicide gene therapy. (1998) (31)
Inducible expression of V600EBraf using tyrosinase‐driven Cre recombinase results in embryonic lethality (2010) (30)
Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression (2011) (30)
A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages (2014) (30)
Deja Vu: EGF receptors drive resistance to BRAF inhibitors. (2013) (29)
Erythropoietin-stimulated Raf-1 tyrosine phosphorylation is associated with the tyrosine kinase Lyn in J2E erythroleukemic cells. (2001) (28)
Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents. (2013) (27)
A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh/AXLlow melanoma (2018) (27)
An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma (2007) (26)
Is BRAF the Achilles' Heel of Thyroid Cancer? (2006) (25)
Mind the IQGAP. (2013) (25)
2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth (2019) (25)
Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold. (2008) (24)
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF. (2010) (24)
Isolation and characterization of SRF accessory proteins. (1993) (24)
Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer (2019) (24)
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds (2010) (23)
Intravital imaging reveals conversion between distinct tumor vascular morphologies and localized vascular response to Sunitinib (2013) (23)
Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems. (2004) (23)
Genetic and cellular mechanisms of oncogenesis. (2010) (23)
Transonic, thermodilution, or ionic dialysance to manage vascular access: Which method is best? (2014) (22)
Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group. (2010) (22)
Nodular Melanoma: A Histopathologic Entity? (2018) (22)
Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. (2006) (22)
Advances in Brief V 599 EB-RAF is an Oncogene in Melanocytes (2004) (22)
In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug (2000) (21)
FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (20)
Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT. (2003) (20)
Preliminary results of an open labelled phase 2 study evaluating the safety and efficacy of sorafenib in metastatic advanced thyroid cancer (2008) (20)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”, Napoli, December 5th-8th 2013 (2014) (19)
Identification of Inhibitors of the Kinase Activity of Oncogenic V600EBRAF in an Enzyme Cascade High-Throughput Screen (2006) (19)
Ultraviolet radiation drives mutations in a subset of mucosal melanomas (2021) (17)
Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells (2016) (17)
14-3-3 proteins: structure resolved, functions less clear. (1995) (17)
Application of sequencing, liquid biopsies and patient-derived xenografts for personalized medicine in melanoma (2016) (16)
Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma. (2013) (15)
Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma (2020) (15)
BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring. (2010) (15)
Raf phosphorylation: one step forward and two steps back. (2005) (15)
V600E Braf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG (2010) (13)
Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients (2017) (13)
Monoclonal antibodies to protein kinase C gamma. Functional relationship between epitopes and cofactor binding sites. (1989) (13)
A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs (2003) (13)
Appropriate subcellular localisation of prodrug‐activating enzymes has important consequences for suicide gene therapy (2001) (13)
Expression of kinase suppressor of Ras in the normal adult and embryonic mouse. (2002) (12)
Molecular analysis of single circulating tumour cells following long‐term storage of clinical samples (2017) (12)
BRAF as a therapeutic target: a patent review (2006 – 2012) (2013) (12)
Inactivation of TGFb receptors in stem cells drives cutaneous squamous cell carcinoma (2016) (12)
Dephosphorylation of the human T lymphocyte CD3 antigen. (1989) (12)
Purification of protein kinase C isotypes from bovine brain. (1991) (11)
Cancer: Melanoma troops massed (2009) (11)
Taking the stress out of melanoma. (2009) (11)
Cost‐effectiveness of a policy‐based intervention to reduce melanoma and other skin cancers associated with indoor tanning (2022) (10)
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers (2020) (9)
A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia (2015) (9)
Regulation of Ras z GTP Loading and Ras-Raf Association in Neonatal Rat Ventricular Myocytes by G Protein-coupled Receptor Agonists and Phorbol Ester ACTIVATION OF THE EXTRACELLULAR SIGNAL-REGULATED KINASE CASCADE BY PHORBOL ESTER IS MEDIATED BY Ras* (1999) (9)
New insights into naevoid melanomas: a clinicopathological reassessment (2017) (9)
New insight puts CRAF in sight as a therapeutic target. (2011) (9)
MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer (2022) (8)
The EGF receptor Hokey-Cokey. (2007) (8)
G12DNRAS and kinase‐dead BRAF cooperate to drive naevogenesis and melanomagenesis (2014) (8)
Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin (2018) (7)
All roads lead to the ribosome. (2010) (7)
Twenty-fourth annual Pezcoller symposium: Molecular basis for resistance to targeted agents. (2013) (7)
Definition of Biologically Distinct Groups of Conjunctival Melanomas According to Etiological Factors and Implications for Precision Medicine (2021) (7)
Molecular characterization of fast-growing melanomas. (2021) (7)
Purification and characterisation of bovine brain protein kinase C isotypes alpha, beta and gamma. (1989) (7)
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma (2017) (7)
[Murine cutaneous melanoma models. Importance of the genetic background]. (2011) (6)
Childhood papillary thyroid cancer as second malignancy after successful treatment of rhabdomyosarcoma (2008) (6)
(V600E)Braf::Tyr-CreERT2::K14-Kitl mice do not develop superficial spreading-like melanoma: keratinocyte Kit ligand is insufficient to "translocate" (V600E)Braf-driven melanoma to the epidermis. (2012) (6)
Studies on the primary sequence requirements for PKC-alpha, -beta 1 and -gamma peptide substrates. (1990) (6)
Erratum, The role of B-RAF in melanoma (2005) (5)
Mitogen Activated Protein Kinase Cascades as Therapeutic Targets in Cancer. (2002) (5)
Methods to improve efficacy in suicide gene therapy approaches: targeting prodrug-activating enzymes carboxypeptidase G2 and nitroreductase to different subcellular compartments. (2004) (4)
T cell immune awakening in response to immunotherapy is age-dependent (2021) (4)
1628O Development of the Manchester Cancer Research Centre Molecular Tumour Board for matching patients to clinical trials based on tumour and ctDNA genetic profiling. (2017) (4)
Protein kinase C as a second messenger target. (1989) (4)
So You Can Teach Old Fibroblasts New Tricks. (2016) (4)
Publisher Correction: Ultraviolet radiation–induced DNA damage is prognostic for outcome in melanoma (2018) (4)
CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma. (2021) (4)
Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma (2020) (4)
Map3k1 Loss Cooperates With BrafV600E to Drive Melanomagenesis. (2020) (3)
KIT and BRAF Mutational Status in a Patient with a Synchronous Lentigo Maligna Melanoma and a Gastrointestinal Stromal Tumor (2012) (3)
TARGET trial: Molecular profiling of circulating tumour DNA to stratify patients to early phase clinical trials. (2016) (3)
Braking BRAF: AMPK leaves ERK stranded in the desert. (2013) (3)
Onco-STS: a web-based laboratory information management system for sample and analysis tracking in oncogenomic experiments (2014) (3)
Current models, challenges and best practices for work conducted between European academic cooperative groups and industry (2020) (3)
Use of circulating tumor DNA to predict survival in patients with resected high-risk stage II/III melanoma. (2017) (3)
Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia. (2011) (3)
Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models (2016) (3)
The TARGET trial: Molecular profiling of circulating tumour DNA to stratify patients to early phase clinical trials (2016) (3)
The biology and oncology of RAF–ERK signaling (2008) (2)
Correction: In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors. (2019) (2)
A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in patients with advanced solid tumours, including metastatic melanoma. (2016) (2)
Erratum: Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma (Cancer Cell (2015) 27(1) (85–96) (S1535610814004577) (10.1016/j.ccell.2014.11.006)) (2017) (2)
Cancer: Tumours addicted to drugs are vulnerable (2017) (2)
Meeting report from the “ Melanoma Research : a bridge from Naples to the World . Napoli , December 5 th – 6 th 2011 ” (2012) (2)
C‐end your drugs using peptide tags (2010) (2)
The need for exercise rehabilitation in Botswana. (2008) (2)
Melanoma Metabolism (2019) (2)
Corrigendum: Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53 (2015) (2)
A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia. (2015) (2)
Abstract 3207: Influence of tumor mutation burden on response to anti-PD-1 treatment in murine models of melanoma (2016) (2)
Mood states and health behaviours in paramedical first-year students. (1990) (2)
Histology and immunohistochemistry (2010) (2)
MEK 1 / 2 inhibition decreases lactate in BRAF-driven human cancer cells (2013) (1)
Sunglasses to hide behind may also prevent melanoma of the eyes (2021) (1)
Abstract 5685: An evaluation of DNA and RNA based blood biomarkers in prostate cancer (2017) (1)
Abstract LB-212: Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models (2016) (1)
Tumour infiltrating B cells discriminate checkpoint blockade-induced responses. (2022) (1)
IL-16 B-Raf in melanoma (2003) (1)
Oral Presentations 1 (2004) (1)
Hooked on UVR (2014) (1)
MAPK pathway activation in the embryonic pituitary results in stem cell compartment expansion, differentiation defects and provides insights into the pathogenesis of papillary craniopharyngioma (2017) (1)
Abstract B11: Mouse models of melanoma driven by oncogenic NRAS (2014) (1)
Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations (2014) (1)
Author Correction: The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival (2021) (1)
Gene regulation in cancer gene therapy strategies. (2003) (1)
Abstract 4167: Ultraviolet radiation cooperates with individual oncogenes to drive melanomagenesis through distinct molecular mechanisms (2016) (1)
The Transcription Factor B-Myb is Phosphorylated and Activated by Cyclin A/Cdk2 (1998) (1)
A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM). (2011) (1)
Preparation of 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for treating cancer (2013) (1)
Comparative studies on protein kinase C isotypes (1989) (1)
Corrections to Pyridoimidazolones as Novel Potent Inhibitors of v-Raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) (2009) (1)
Abstract 1561: Gene expression analysis identifies heterogeneity in cutaneous melanoma subjects with disruptiveMC1Ralleles andBRAFhotspot mutations (2017) (1)
Circulating tumour DNA analysis predicts relapse following resection in stage II and III melanoma. (2018) (1)
Frequent loss of function mutations in TGF beta R1 and TGF beta R2 implicate hair follicle bulge stem cells as a cell of origin of cutaneous squamous cell carcinoma. (2016) (1)
Abstract 3404: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. (2013) (1)
Abstract 5166: Lysyl oxidase regulates cell surface EGFR, and directionality of cancer cell invasion (2018) (0)
Abstract SY17-01: BRAF and RAS signaling in melanoma: Basic biology to clinical exploitation. (2013) (0)
Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface (2017) (0)
Ultraviolet radiation drives mutations in a subset of mucosal melanomas (2021) (0)
Abstract 2432: A technology platform for personalized medicine in melanoma (2015) (0)
Cancer esearch apeutics , Targets , and Chemical Biology ovel , Selective , and Efficacious Nanomolar R idopyrazinone Inhibitor of V 600 EBRAF (2010) (0)
Abstract 2683: Simultaneous inactivation of TP53 and loss of PTEN diminish response to targeted therapy in V600EBRAF mutant melanoma (2015) (0)
– Prostate Cancer Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and-nonvisible Lesions in Clinically Localised Prostate Cancer (2018) (0)
UM Cure 2020 − A consortium of European experts in uveal melanoma to identify new therapies for patients with metastatic disease (2016) (0)
141 Targeting TGFβ signaling in BRAF mutant melanoma (2017) (0)
Physiological changes associated with lateral movement training of netball players (2000) (0)
272: TWIST1 and ZEB1 EMT inducers contribute to melanoma development through regulating MITF (2014) (0)
Rasrecruits Raf-1 totheplasmamembranefor activation bytyrosine phosphorylation (1995) (0)
540 Vemurafenib alters glucose utilization in BRAF-driven human melanoma cells (2014) (0)
A Comparative Study of the Physical Fitness of Physical Education and Non-physical Education University Students in Botswana (2007) (0)
Abstract IA18: Moving towards precision medicine for melanoma (2017) (0)
BRAF inhibition promotes BRAF mutant human melanoma cell survival under nutrient-deprived conditions through activation of mitochondrial metabolism (2016) (0)
Abstract 4307: Paradoxical activation of the MEK/ERK pathway promotes melanoma invasion and metastasis. (2013) (0)
Gene-specific interactions between ultraviolet radiation and melanoma (2016) (0)
Abstract 422: Lymph node metastasis evolution drives immune evasion and targeted therapy resistance in gastro-esophageal adenocarcinomas (GEAs) (2017) (0)
Mutant BRAF confers transforming growth factor b addiction (2016) (0)
Melanoma therapy: from frustration to enthusiasm (2012) (0)
441 The discovery of novel, highly potent inhibitors of BRAF (2010) (0)
Metabolic rewiring in melanoma cell lines that acquired resistance to BRAF inhibitors (2016) (0)
Surface expression of an enzyme in gene therapy based prodrugs. (1995) (0)
Abstract 3994: Genomic characterization of melanoma in the elderly reveals molecular drivers of progression and prognosis associated with immunotherapy response (2019) (0)
Assessing the interplay of RNA-fusion events with cancer driver mutations in melanoma patients (2016) (0)
Abstract 1506: Frequent loss of function mutations in TGFβR1 and TGFβR2 identify hair follicle bulge stem cells as the cell of origin for cutaneous squamous cell carcinoma (2015) (0)
Rod specific phosphodiesterase 6 regulates human melanoma cell cytoskeleton (2008) (0)
167 INVITED Pre-clinical studies of BRAF signalling in cancer (2007) (0)
Evolutionary Routes in Metastatic Uveal Melanomas Depend on Alterations (2020) (0)
Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in precision-medicine oriented early phase clinical trials (2018) (0)
Surface expression of the enzymes in the reoriented prodrug therapy (1995) (0)
UM Cure 2020 - A consortium of European experts in uveal melanoma to identify new therapies for patients with metastatic disease (2016) (0)
Publisher Correction: Ultraviolet radiation–induced DNA damage is prognostic for outcome in melanoma (2018) (0)
Molecular characterization of fast-growing melanomas supplementary data (2021) (0)
Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface (2019) (0)
Abstract 4844: CRISPR-generated BAP1 knockdown in uveal melanoma cell lines affects organotropism (2017) (0)
168 L597VBRAF Acts as an Epistatic Modifier of G12DKRAS (2012) (0)
The journey from melanocytes to melanoma. (2023) (0)
New insights into naevoid melanomas : a clinico-pathological reassessment (2017) (0)
Proffered Paper: Utilising non-mutational drug-tolerance prolongs and improves targeted melanoma therapy (2016) (0)
UM Cure 2020: New therapies for uveal melanoma (2018) (0)
Correction to: Journal of Investigative Dermatology (2013) 133, 274–276; doi:10.1038/jid.2012.268; published online 16 August 2012 (2013) (0)
Somatic mutations in the cancer associated GPCR-like protein smoothened (2008) (0)
Abstract 470: Application of sequencing, liquid biopsies and patient derived xenografts for personalized medicine in melanoma (2016) (0)
Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma (2020) (0)
ヒトカゼインキナーゼII及び[γ‐32P]ATPを用いたりん酸化による組換体断片の放射活性標識化 (1996) (0)
Systematic longitudinal analysis of circulating tumour DNA in melanoma patients undergoing systemic therapy (2016) (0)
Professor Chris Marshall, 1949–2015 (2015) (0)
127 INVITED Basics of BRAF (2011) (0)
Abstract IA1: Keynote Presentation: BRAF and RAS signaling in melanoma from basic to translational and clinical research (2012) (0)
Cancer esearch cular and Cellular Pathobiology ivation of Forkhead Box O Transcription Factors by R ogenic BRAF Promotes p 21 cip 1-Dependent Senescence (2010) (0)
Abstract 905: Lysyl oxidase is required for chemotaxis (2017) (0)
FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (0)
Abstract 2400: Mechanisms of resistance to immuno and targeted therapies in acral melanoma (2016) (0)
Prostate cancer: A personalised approach through the development of patient-derived xenografts (2016) (0)
On the potential beneficial effects of indoor tanning: reply from the authors (2022) (0)
584 POSTER Novel inhibitors of BRAF based on a 2,6-disubstituted pyrazine scaffold (2008) (0)
The Changing Epidemiology of Desmoplastic Melanoma (2023) (0)
20 B-RAF is an oncogene and therapeutic target in melanoma (2004) (0)
Abstract 2677: Lysyl Oxidase a therapeutic target in pancreatic cancer (2014) (0)
Abstract 3393: Genomic analysis of multi-site fresh prostate samples (2017) (0)
Abstract 469: Systematic analysis of circulating tumor DNA in melanoma patients to uncover mechanisms of resistance and disease clonality (2016) (0)
Compounds which can be used for the production of protein-tyrosine kinase inhibitor prodrugs (1994) (0)
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013 (2014) (0)
385 INVITED The Role of BRAF and KRAS in Melanoma Progression (2011) (0)
Abstract 5024: Implications of MAPK pathway inhibition on monocytes and tumor-associated macrophages in melanoma (2015) (0)
Christopher Marshall (1949–2015) (2015) (0)
97 The Basics of Melanoma Cell Signalling (2012) (0)
Improvements in the preparation of prodrugs (1994) (0)
Tumour–microenvironment mediates resistance to immuno and targeted therapies in acral melanoma (2016) (0)
330 BRAF and RAS signalling in human melanoma (2008) (0)
Abstract 1144: Cell plasticity mediated by EMT-inducing transcription factors contributes to melanoma development (2014) (0)
Kinase inactive Braf drives aneuploidy by deregulation of Craf (2010) (0)
Modelling anti-PD-1 treatment in a transgenic murine model of BRAFV600E-driven melanoma (2016) (0)
A novel circulating tumour cell-derived xenograft (CDX) model to investigate uveal melanoma metastasis. (2018) (0)
Paradoxical activation of the MEK/ERK pathway promotes melanoma invasion and metastasis (2012) (0)
The Major Vault Protein ( MVP ) Mediates Starvation Resistance of Human Glioblastoma Cells Via Deregulation of the PI 3 kinase Pathway (2012) (0)
Abstract 1094: Deciphering driver mechanisms for tumorigenesis in BRAF/NRAS double wild-type melanoma through integration of heterogeneous genome-wide datasets (2015) (0)
INV 32 BRAF signalling in cancer: biology and therapeutic opportunities (2007) (0)
Abstract PL04-04: Developing circulating tumor cell derived explant models (CDX) (2016) (0)
Editorial Board (2009) (0)
431 Opposite Roles of Embryonic EMT-inducers in B-Raf-driven Melanocyte Transformation (2012) (0)
Abstract 5201: Elucidating distinct roles for NF1 in melanomagenesis. (2013) (0)
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study (2019) (0)
RAS and RAF signaling in melanoma: biology and therapies (2010) (0)
INV 27 Phase I trial of sorafenib (BAY 43-9006) combined with dacarbazine (DTIC) in patients with metastatic melanoma (2007) (0)
D.M. Terrian, G.M. Cencetti (eds). Cancer Cell Signaling: Methods and Protocols (2003) (0)
Inactivation of transforming growth factor-beta receptors in human cutaneous squamous cell carcinoma and murine hair follicle stem cells drives tumorigenesis. (2016) (0)
Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin (2018) (0)
Abstract A185: Combining unbiased network analysis and cancer genomics to guide precision medicine-oriented early-phase clinical trials (2018) (0)
ef fect of SMU r F2 t argeting on Susceptibility to M eK inhibitor s in Melanoma (2012) (0)
167 POSTER A pyrazyne scaffold for the generation of novel inhibitors of B-RAF (2006) (0)
69IN NEW MOLECULAR TARGETS IN MELANOMA (2012) (0)
Expression intracellulaire de carboxypeptidase g2 dans une therapie a base d'enzyme et de promedicament (1995) (0)
Abstract 1130: Unveiling the metabolic response of BRAF mutant melanoma cells to BRAF inhibition (2015) (0)
Abstract 3438: Genetic analysis of melanoma from an albino patient (2018) (0)
Ultraviolet radiation–induced DNA damage is prognostic for outcome in melanoma (2018) (0)
Kinase-Inactivating Braf Mutation Drives Aneuploidy In Splenic Myeloid Cells by Deregulation of Craf (2010) (0)
Abstract 2727: Elucidating genes that mediate brain colonization by metastatic melanoma cells (2020) (0)
Abstract PL02-02: BRAF and RAS signaling in cancer: From biology to therapeutics. (2011) (0)
Abstract PL04-02: Ras and Raf signaling: From biology to therapeutics (2012) (0)
Genomic analysis of multi-site fresh prostate samples (2016) (0)
653 Activating TGF-beta Signalling Enhances the Efficacy of MAP-kinase Pathway Inhibitors in Melanoma (2012) (0)
Genetic and cellular mechanisms of oncogenesis: Editorial overview (2010) (0)
Surface-localized expression of enzymes in gengesteuerter prodrugtherapie (1995) (0)
Abstract 4653: Melanocyte specific deletion ofMap3k1reveals its role in BRAFV600E-driven melanoma (2019) (0)
Metabolism: The Sweet Spot in Melanoma Precision Medicine? (2018) (0)
Lysyl oxidase regulates EGFR signalling through the extracellular matrix (2016) (0)
The role of BAP1 loss of function in uveal melanoma (2016) (0)
Protein kinase C--structural studies. (1988) (0)
Imidazo [4,5-b] pyridin-2-one and analogues thereof as therapeutic compounds against cancer (2007) (0)
Explorer Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells (2017) (0)
MOLECULAR LANDSCAPE OF OLD AGE MELANOMA BY SURVIVAL AND IMMUNOTHERAPY RESPONSE (2021) (0)
Therapeutics , Targets , and Chemical Biology MEK 1 / 2 Inhibition Decreases Lactate in BRAF-Driven Human Cancer Cells (2013) (0)

This paper list is powered by the following services:

Other Resources About Richard Marais

en.wikipedia.org

What Schools Are Affiliated With Richard Marais?

Richard Marais is affiliated with the following schools:

Image Attributions

Image Source for Richard Marais